Systems, devices and methods for resuscitation

ABSTRACT

Methods, devices, systems of resuscitating a patient including accessing an arterial vessel positioning a catheter into the arterial vessel advancing the catheter through the arterial vessel to position it below a vessel supplying blood to a heart and a brain expanding an expandable portion of the catheter to prevent blood from flowing past the expanded portion and infusing a substance retrograde into the artery within the arterial section between the heart and the expanded portion of the catheter.

RELATED APPLICATION DATA

This application is a continuation of U.S. application Ser. No.15/373,034 filed Dec. 8, 2016 which claims the benefit of U.S.Provisional Application No. 62/265,336 filed Dec. 9, 2015, theentireties of which are incorporated by reference herein. Thisapplication also incorporates by reference U.S. Provisional No.61/727,302 filed on Nov. 16, 2012, entitled RESUSCITATION SYSTEM ANDMETHOD OF USE; and U.S. patent application Ser. No. 14/083,192 filed onNov. 18, 2013, entitled SYSTEMS, DEVICES AND METHODS FOR RESUSCITATION.

FIELD OF THE INVENTION

The present invention relates to an injection system for administeringmedical substances into tissue. Variations of the device and methoddescribed herein allow for an automated injector for administration ofmedications under the skin or into the muscle of patients. Furthervariations include injection systems designed to reside on an individualwhere injection of the substance can occur when needed and on-demand.

BACKGROUND

The survival rate is relatively low for a person, whether in a medicalsetting or elsewhere, is relatively low. One of the reasons for the highmortality rate is that cardiopulmonary resuscitation (CPR), one of theprimary resuscitation methods, induces little forward blood flow.Although certain drugs, such as epinephrine, can improve vital organblood flow during CPR, these drugs are administered almost exclusivelyinto a vein; as such, the drug must circulate to and through the heartand lungs before arriving at the peripheral arteries where their primarybeneficial pharmacological effects occur. During this low blood state ofCPR, the heart and brain receive very limited blood flow blood that mayfail to sustain cellular survival.

Invasive techniques such as open-chest cardiac massage (OCCM), directmechanical ventricular assistance (DMVA), and cardiopulmonary bypass(CPB) can provide better vital organ blood flow. See generally R.Bartlett et al., Ann. Emerg. Med. 13(Part 2), 773-777 (1984); M. Anstadtet al., Resuscitation 21, 7-23 (1991); P. Safar et al., Am. J. Emerg.Med. 8, 55-67 (1990). However, adaptation of these techniques forwidespread use, particularly in a setting outside a hospital, isunrealistic. In most cases, the response time that would enablesignificant neurologic recovery would likely expire before thesetechniques could be employed in a typical emergency.

Selective aortic arch perfusion (SAAP) is a technique designed toprovide relatively isolated perfusion of the heart and brain in patientssuffering cardiac arrest. SAAP is typically performed by inserting alarge lumen balloon occlusion catheter, percutaneously or by surgicalcutdown, into a femoral artery and then advancing the catheter tip tothe descending aortic arch, preferably just distal to the leftsubclavian artery. With the SAAP catheter balloon inflated to prevent orrestrict distal aortic flow, the coronary and cerebral circulations canbe relatively selectively perfused with a solution infused via the lumenof the SAAP catheter. The infused solution is typically an oxygenatedblood substitute, such as a perfluoro carbon emulsion or polymerizedhemoglobin solution that contains various agents capable of reversingischemic metabolic processes, restoring peripheral vascular resistance,correcting hemostatic derangements, and limiting reperfusion-inducedcellular damage. For example, vasoconstrictors such as epinephrine arebeneficial. Perfusion with such a solution can enhance return ofspontaneous cardiac function and facilitate neuronal functionalrecovery. Catheters intended to occlude the descending aorta aredisclosed by Manning, U.S. Pat. Nos. 5,678,570, 5,216,032, and Paradis,U.S. Pat. No. 5,334,142 each of which is incorporated by referenceherein.

Although research indicates that SAAP shows promise, the technique hascertain shortcomings. SAAP is a volume loading procedure and, as such,is volume limiting. When excess volumes of protective solution areinfused, as may happen if an initial SAAP infusion is insufficient toresuscitate the patient and is followed by subsequent infusions,pulmonary congestion and edema can result, each of which can have asignificant adverse effect on pulmonary oxygenation. The conventionaldevices do not optimally address avoidance of volume overload duringSAAP.

SUMMARY OF THE INVENTION

The devices and methods described herein improve shortcomings in SAAPtreatment. The disclosure includes methods and devices for resuscitatinga patient. For example, the method can include accessing an arterialvessel; positioning a catheter into the arterial vessel; advancing thecatheter through the arterial vessel to position it below a vesselsupplying blood to a heart and a brain; expanding an expandable portionof the catheter to prevent blood from flowing past the expanded portion;infusing a substance retrograde into the artery within the arterialsection between the heart and the expanded portion of the catheter.

In a variation of the method, accessing the arterial vessel involvesidentifying the location of the arterial vessel by a technique selectedfrom the group consisting of: a) feeling for a pulse and inserting theaccess device at the pulse; b) using ultrasound; c) using an electricfield; d) using a magnetic field disturbance; and e) using tissuedensity differences.

In another variation, where positioning the catheter further comprisesplacing a needle through the skin and overlying tissue into the artery;placing a wire through the needle; and placing the catheter over theneedle or over the wire after removing the needle.

The method can also further comprise determining the position below thevessel supplying blood to the heart and the brain is determined by atechnique selected from the group consisting of: a) determining thedistance from the access site to a desired position external to thepatient and advancing the catheter to said predetermined distance; b)using xray to place the catheter into appropriate position and to verifythat the catheter is in appropriate position; c) detecting a signal fromthe catheter (light, sound, ultrasonic, heat, cold, electromagnetic todetermine placement position.

In another variation, expanding the expanded portion comprises a deviceselected from the group consisting of a) a balloon catheter; b) acatheter with an umbrella structure; c) a catheter having a mechanicallyexpanding spheroid.

The substances used in the methods and device can include a) blood; b)oxygen carrier such as a perflourocarbon; c) calcium; d) EDTA; e)saline; f) cooling or warming fluid.

The retrograde infusion can be continuous or pulsatile.

A variation of the method includes the retrograde infusion supplied at arate and or pressure sufficient to close the aortic valve.

The devices described herein also include a catheter capable ofperforming the methods described here. Such a catheter can have thefollowing characteristics: a) a proximal end; a distal end; a lumenconnecting the proximal end to the distal end; an occluding part at thedistal end that can be activated from outside the patient to occlude theflow of fluid on the outside of the lumen past itself.

The occluding part of claim can be one of the following: a balloon; anexpandable covered cage; side port suction that draws vessel around thepart.

In a variation, the device can include a pump to inject fluid from theproximal end of the device described herein such that it flows to thedistal end of the catheter and into the blood vessel in a retrogradedirection so as to increase the pressure in the vessel and close a valvesuch as the aortic valve when the vessel is the aorta, thereby directingflow of the injected fluid into side branches of the vessel such is intothe coronary arteries and carotid arteries.

The disclosure also includes an infusion substance that consists of atleast one of the following: saline; oxygen carrier such as blood or afluorocarbon based oxygen carrier; epinephrine; atropine; calciumchelator such as EDTA, calcium salts such as calcium gluconate andcalcium carbonate.

Another device includes a device for locating and cannulating a bloodvessel consisting of a channel through which a needle or catheter can beplaced from the outside of a patient to the inside of a blood vessel, afeedback system that provides information to the user that further makesit possible for the vessel to be located and for the catheter to beplaced therein. Such a feedback method can include a least one of thefollowing: a light pattern; a color change; a screen showing an image; asound; a vibration; a temperature change;

The light pattern described herein can include light changing from redto green when the device of claim 5 is correctly placed over a bloodvessel to allow cannulation.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic illustration of a balloon catheter insertedthrough the femoral artery into the aorta in a human subject proximal tothe diaphragm but distal to the left subclavian artery, with the ballooninflated to block the descending aorta.

FIG. 2 is an enlarged partial view of the heart and balloon catheter ofFIG. 1 showing the balloon catheter positioned to block the descendingaorta and perfuse the aortic arch.

FIG. 3 is a schematic illustration of a triple lumen balloon catheterhaving a blood withdrawal line configured to withdraw blood from thedistal aorta.

FIG. 4 is a schematic representation of a blood withdrawal catheterhaving an anticoagulant infusion port.

FIG. 5 is a schematic illustration of an exemplary SAAP system and itscatheter extending into the femoral artery of a subject.

FIGS. 6A and 6B illustrate variations of devices that rely on aperfusion substance to inflate an occlusive expandable member.

FIGS. 7A and 7B illustrate a partial cross sectional view of theexpandable member showing a valve located within the expandable member.FIG. 7B illustrates the valve in a closed position.

FIGS. 8A and 8B illustrate the valve in a closed position and in areleased position using a release mechanism.

DETAILED DESCRIPTION

The present invention will now be described hereinafter in detail withreference to the accompanying drawings. The present invention is not,however, limited to the embodiments described herein; rather, theseembodiments are intended to enable those skilled in this art tounderstand fully the invention.

As described above, the disclosure is directed to methods and associatedapparatus for treating a subject in cardiac arrest. As used herein, theterm “cardiac arrest” refers to all types of cardiac arrest, includingventricular fibrillation, asystole, and pulseless electrical activity.The subject of such cardiac arrest can be mammalian and more preferablyhuman, but can be any animal that can be advantageously treated byoxygenating its brain and coronary vasculature during cardiac arrest.

Blocking of the descending aorta, and infusion into the aortic arch, canbe carried out with a balloon catheter unit such as that illustrated at5 in FIG. 1 . The balloon catheter unit 5 comprises an elongate cathetertube 6 having a primary lumen 7 through which protective solution maypass, and further comprises a balloon 8 at one end of the elongate tube6 configured to be inflated to block the descending aorta of a humansubject. A secondary tube 9 (or alternatively a secondary lumen formedin the wall of the tube 6 and extending longitudinally therewith)provides a mechanism for inflating the balloon 8 once the balloon 8 ispositioned in the desired location within the descending aorta of thesubject. A connector such as a Leur Lock™ fitting is provided at the endof the elongate tube 6 opposite the balloon 8 to connect the cathetertube 6 to a supply for the protective solution.

For a human adult, the size of the primary lumen 7 may be from 6 Frenchto 14 French, the length of the catheter tube 6 may be from 50 to 150centimeters, the inflated dimensions of the balloon 8 may be from 1.5 to4 centimeters in diameter, the length of the balloon 8 may be from 2 to10 centimeters, and the distance from the tip of the catheter tube 6 tothe balloon 8 distance may be from 1 to 4 centimeters. For a humanchild, the lumen size may be from 5 French to 10 French, the cathetertube length may be from 20 to 80 cm, the balloon inflated dimensions maybe from 0.75 to 2 cm in diameter, the balloon length may be 1.5 to 6 cm,and the catheter-tip to balloon distance may be from 0.5 to 2 cm. Wheninflated, the balloon 5 should be capable of withstanding a pressure ofat least 300 to 500 mmHg to prevent leakage of protective solution downthe descending aorta and rupture of the balloon during chestcompression.

The catheter tube 6 may be made from a firm but somewhat flexibleplastic material, and the balloon 8 from a latex or polyurethanematerial. The catheter tube 6 may be made from antithrombotic materials,such as having heparin bonding as a characteristic of construction, toinhibit formation of blood clots in the aorta. Reference may be made toU.S. Pat. Nos. 5,049,132; 5,049,131; 5,045,061; 5,042,976; 5,041,125;and 5,216,032 for further guidance in the construction of the ballooncatheter. It is specifically intended that the disclosures of all patentreferences cited herein be incorporated herein by reference.

To block the descending aorta of the subject (FIGS. 1 and 2 ), theballoon catheter unit 5 is inserted into a femoral artery 10 of thesubject and advanced within the descending aorta 11 past the renalarteries 12, 13, the superior mesenteric artery 14, the celiac trunk 15,the diaphragm 16, and past various ones of the intercostal arteries 17.The balloon 8 can be positioned distal to the carotid arteries 22, 24and the left subclavian artery 21, but can be located at least proximalto the renal arteries 12, 13. The balloon 8 is inflated via thesecondary tube 9 to block the descending aorta 11, with the leading endof the elongate tube 6 positioned to perfuse the aortic arch 20. In thisposition, protective solution pumped or forced through the ballooncatheter unit 5 and exiting the balloon 8 will perfuse the leftsubclavian artery 21, the left common carotid artery 22, thebrachiocephalic trunk 23 (and in turn the right carotid artery 24 andthe right subclavian artery 25) and the coronary arteries 26, 27.Although some variations block the descending aorta with a ballooncatheter as illustrated, those skilled in this art will appreciate thatother means for blocking the descending aorta to prevent flow thereincan also be used with the present invention.

Withdrawing the subject's blood can be carried out in any manner knownto those skilled in this art to be suitable therefor. One technique ofwithdrawing autologous blood from the subject is to insert a catheterinto the femoral vein (or some other large vein, such as the jugularvein or subclavian vein). This technique would allow blood to becontinuously withdrawn and infused. Another technique would be towithdraw the blood from the proximal aorta with the balloon of theballoon catheter deflated. An alternative technique would involvewithdrawing blood from the distal aorta with the balloon inflated, whichis beneficial due to the capability of continuous infusion andwithdrawal. A catheter embodiment for such withdrawal is illustratedschematically in FIG. 3 . A balloon catheter unit 30 comprises two largelumens: an infusion lumen 31 that terminates beyond the balloon 32; anda blood withdrawal lumen 33 that terminates prior to the balloon 32. Aballoon inflation line 34 terminates within the balloon 32. Thisembodiment enables blood to be withdrawn into the blood withdrawal lumen33 either when the balloon 32 is deflated or inflated when the inlet 35of the blood withdrawal lumen 33 is positioned in the distal aorta.

Once blood is withdrawn from the subject, it can be mixed with ananticoagulant to keep the blood from coagulating. Exemplaryanticoagulants include heparin, acid citrate dextrose, or sodiumcitrate. Typically, the anticoagulant is simply added via a syringe to aconduit containing the withdrawn blood. Alternatively, anticoagulant canbe added within a withdrawing catheter prior to the blood actuallyexiting the subject. A catheter configured for such use, designated at36, is illustrated schematically in FIG. 4 . An anticoagulant infusionline 37 terminates within and near the end of the blood withdrawal lumen38. This catheter configuration enables anticoagulant to be introducedinto the blood as the blood enters the catheter, and thus can reduce thedegree of coagulation experienced by that blood. This catheterconfiguration can be combined with that described above in FIG. 3 toenable blood withdrawn from the distal aorta to receive anticoagulantjust as it leaves the bloodstream.

After withdrawal, the blood is then oxygenated. Oxygenation can beperformed in any manner known to those skilled in this art to oxygenateblood. For example, blood can be shunted into a tank or reservoir havingan oxygen membrane and passed therethrough.

In a variation the withdrawn blood be passed through a filter or otherdevice that removes any blood clots or other debris prior to reinfusion,as such debris can adversely affect perfusion.

Once the blood is oxygenated, it can be infused into the aorta of thesubject. Typically between about 250 to 3000 milliliters of the bloodare infused, with 750 to 2000 milliliters of the blood being a morepreferred dosage. Perfusion should be carried out sufficiently rapidlyto enhance cardiac electrical activity; in one variation, the perfusionduration is less than five minutes.

Perfusion of the newly-oxygenated blood can be carried out continuously,or preferably can be carried out in a pulsatile rhythm. Perfusion with apulsatile rhythm can assist in removing sludged blood cells from themicrovasculature of the subject and may have positive effects onresuscitation due to the rheology of blood. In particular, perfusionwith a pulsatile rhythm in which the perfusion “pulses” are timed tocoincide with the decompression or relaxation phases of CPR (diastolicpulsing) can be especially effective.

A vasoconstrictor may be employed in the methods described herein.Exemplary adrenergic vasoconstrictors include epinephrine,norepinephrine, methoxamine, phenylephrine, with epinephrine beingpreferred; nonadrenergic vasoconstrictors can also be used.Vasoconstrictors may be administered by any suitable means, such as byparenteral injection (e.g., intravenous injection, intraarterialinjection, subcutaneous injection, intramuscular injection,intraperitoneal injection, tracheobronchial administration), or byincluding the vasoconstrictor in the protective solution used to perfusethe aortic arch. In a variation the administration of thevasoconstrictor be concurrent with (i.e., sufficiently close in time to)perfusion of the aortic arch so that the vasoconstrictor will affectcoronary perfusion with the autologous blood. The dosage of thevasoconstrictor will vary depending on the subject and the particularvasoconstrictor chosen, but will generally be between 0.002 and 0.3mg/kg.

Medicaments containing a vasoconstrictor for enhancing coronaryperfusion with a protective solution during selective aortic archperfusion may be prepared by contacting and mixing the vasoconstrictorwith a pharmaceutically acceptable carrier, such as a sterilepyrogen-free saline solution, in accordance with techniques known in thepharmacy art. The pharmaceutical carrier may be the protective solutionitself, such as a perfluorochemical blood-substitute solution asdiscussed above.

Restoring spontaneous circulation in the subject may be carried out byany suitable means, such as electric shock or precordial thump (i.e.,application of an external force), or by enhancing electrical activitythrough perfusion and other resuscitation techniques so that normalelectrical activity re-emerges without application of an external force.An electric shock to heart muscle tissue which will restore spontaneouscirculation from a chaotic electrical signal (or “defibrillation”) maybe administered with any suitable defibrillator, such as the Responder™1500 (manufactured by Marquette Electronics, Milwaukee, Wis.).

An exemplary SAAP apparatus 40 is schematically illustrated in FIG. 3 .The apparatus 40 comprises a storage tank 41 having two upper ports 43,44, and a lower port 45. A venous blood withdrawal line 46 is attachedat one end to upper port 43 and at its other end to a venous bloodwithdrawal catheter 47 by a fitting 48. The venous blood withdrawalcatheter 47 is to be inserted into the femoral vein of a subject. Ananticoagulant syringe 49 is also fluidly connected to the fitting 48 viaa catheter, connector, or connector tubing 50. An oxygenated bloodinfusion line 51 is attached at one end to the lower port 45. As theoxygenated blood infusion line 51 extends away from the lower port 45,it meets with and travels adjacent to the venous blood withdrawal line46. The adjacent sections of the lines 46, 51 are enclosed within aroller pump apparatus 52, which comprises a pair of wheels 53 mounted ona rotary arm 54. Rotation of the arm 54 causes the wheels 53 to contactthe lines 46, 51 and thereby deliver blood or a blood substitute to andfrom the SAAP apparatus 40. At its outlet end, the oxygenated bloodinfusion line 51 meets the outlet end of an oxygenated bloodrecirculation line 55 that extends thereto from the upper port 44. Aninfusion line 56 extends from the junction of the lines 51, 55 to aninfusion port 57 that is connected to the inlet end of a ballooncatheter (not shown) that is to be inserted in the femoral artery of asubject. A syringe 42 is fluidly interconnected with the infusion line56. The storage tank 41 also includes an oxygen intake port 58 and anadditional syringe port 59. The venous blood withdrawal line 46 alsoincludes an oxygen intake port 60 between the fitting 48 and the rollerpump apparatus 52. Three valves 61, 62, 63 are located, respectively,adjacent the fitting 48 on the venous blood withdrawal line 46, on theoxygenated blood recirculation line 55, and on the infusion line 56between the syringe 42 and the infusion port 57. A fourth valve 67 islocated on the oxygen intake port 60. A controller 65 is operablyconnected with the syringe 42 to control its operation and is alsooperably connected with a CPR device (indicated schematically at 66).The apparatus 40 may also include a valve (not shown) that can removeany air that enters the system prior to its being introduced into thesubject's aorta.

In operation, autologous blood is drawn from the subject into thefemoral venous blood withdrawal catheter 47. Anticoagulant, such asheparin, is added to the withdrawn blood through the anticoagulantsyringe 49. The venous blood is pumped through the venous bloodwithdrawal line 46 by the roller pump apparatus 52; as the rotary arm 54rotates, the wheels 53 provide a positive pressure of the blood thatforces it through the line 46. The venous blood enters the storage tank41 through upper port 43 and flows into the bottom portion of thestorage tank 41. Oxygen is continuously introduced into the storage tankthrough the oxygen intake port 58. After the blood is oxygenated in thestorage tank 41, it flows therefrom through the lower port 45 into theoxygenated blood infusion line 51. The blood is propelled by the actionof the roller pump unit 52 to the infusion line 56. Flow into theoxygenated blood recirculation line 55 is prevented because the valve 62is in a closed position. Oxygenated blood can be furnished in apulsatile rhythm by reciprocating action from the syringe 42. Theoxygenated blood flows through the infusion line 56, through theinfusion port 57, and into the SAAP catheter for delivery to the aorta.

Similarly, this apparatus 40 can also be used to deliver a bloodsubstitute to the subject. See U.S. Pat. No. 5,216,032 to Manning for adiscussion of blood substitutes. The blood substitute can be introducedinto the storage tank 41 through the syringe port 59. The valves 61 and62 are in their closed positions. The blood substitute follows the samepath to the subject as that of oxygenated blood described above.

Further, the apparatus 40 can be used to recirculate, and therebythermally and hemodynamically prepare a blood substitute for perfusion.For recirculation of blood substitute, valve 63 is in its closedposition, and valve 62 is in its open position. This creates a closedloop system that proceeds from the storage tank 41 to the oxygenatedblood infusion line 51, the recirculation line 55, and the upper port 44before returning to the storage tank 41.

Use of the apparatus 40 is exemplified by the following scenario. Aphysician arrives at the scene of a cardiac arrest patient and securesaccess to the femoral artery by either percutaneous or surgical means.The blood substitute is oxygenated during the vascular access procedure.The catheter is advanced to the thoracic aorta and epinephrine isadministered into the aortic arch. The catheter balloon is inflated andan initial SAAP infusion of the blood substitute (which can containreperfusion-injury combating agents) is performed. An initial bolus ofblood substitute is rapidly infused to close the aortic valve and CPR ishalted for the initial infusion lasting 30 to 60 seconds. This wouldassure that the myocardium was effectively perfused with the bloodsubstitute. During this initial infusion, access to a femoral vein issecured. Aortic arch epinephrine administration can be titrated tomaximize CPR-diastolic coronary perfusion pressure (CPP). Two to threeminutes after the initiation of the first blood substitute infusion, asecond blood substitute infusion is initiated. Pulsed diastolic infusioninduced by the syringe 42 using half of the volume initially infusedwould be used to elevate CPP and diminish the volume effects of a secondinfusion. The infusion pulses are administered during the decompressionand relaxation phases of CPR. During the second blood substituteinfusion, femoral blood is withdrawn, anticoagulated via theanticoagulant syringe, oxygenated in the storage tank 41, thermallytreated (if necessary), and filtered in preparation for reinfusion.Depending upon the rapidity of femoral venous access and bloodwithdrawal, either a third blood substitute infusion similar to thesecond or an autologous blood infusion is initiated. Aortic archepinephrine titration, other pharmacologic therapies, and repetitive orcontinuous autologous blood SAAP can be performed until return ofspontaneous circulation (ROSC) is attained or the resuscitative effortsare halted. If ROSC is attained, autologous blood withdrawal andreinfusion could be continued (with or without the catheter ballooninflated depending on the clinical situation) serving as partialcardiopulmonary bypass support for the still unstable cardiovascularsystem in the early post-resuscitation phase. Graded balloon inflationcould be used to provide peripheral resistance as needed in theimmediate and early post-resuscitation phase.

In view of the considerable out-of-hospital use anticipated with thepresent invention, in a variation the SAAP apparatus be packaged to beeasily portable. The apparatus can be packaged in a suitcase, attachecase, backpack, or the like, and be easily carried to the patient foruse by a physician or paramedic.

The present invention may be beneficial in the management of traumaticand other nontraumatic/surgical causes of cardiac arrest or profoundhypovolemia with impending cardiac arrest. In addition to rapid volumereplacement, the catheter balloon could serve much like an aorticcross-clamp to significantly reduce or stop exsanguinating hemorrhagefrom the abdomen, pelvis, or lower extremities until the patient couldbe transferred to the operating room. Clinical situations where thepresent invention can be used include: blunt abdominal or multi-systemtrauma with profound hemorrhage/hypovolemia; penetrating abdominaltrauma with profound hemorrhage/hypovolemia; ruptured abdominal aorticaneurysm with profound hypotension or impending arrest; and major pelvisfractures or disruption. In hemorrhagic/hypovolemic conditions,heterologous human blood, such as from a blood bank, may also beemployed.

Turning now to improved variations, the following devices and/or methodsfurther assist in techniques for resuscitating a patient. The devices,methods, systems and other disclosure contained in U.S. Provisional No.61/727,302 filed on Nov. 16, 2012 are incorporated by reference in itsentirety.

FIG. 6A illustrates another variation of a device 106 having anexpandable member 108, where the device is positioned within the aorta11 such that the distal end 112 is positioned within arterial flow ofblood 2 within the aorta 11. As illustrated in FIG. 6A, an infusedsubstance 3 is infused within a lumen of the device 106. Typically, theinfused substance comprises infused blood. However, other substances arewithin the scope of this disclosure. Regardless, flow of the infusedsubstance within the catheter 106 is diverted within the expandablemember 108. The diversion can be accomplished in any number of ways, forexample, an obturator 110 can be positioned within the device 106 toincrease a fluid flow resistance at the distal end 112 of the device106. The obturator 110 can include an expandable member, a taper orother structure to prevent or resist the flow of the infused substancefrom the distal end 112 of the device 106. The increased resistance toflow causes the infused substance to flow into an expandable member 108,as shown in FIG. 6B. Expansion of the expandable member 108 causinginterruption of arterial flow 2. Flow of the infused substance can occurin a space between the device 106 and the obturator 110. Alternatively,the obturator 110 can include one or more lumens to provide flow ofblood into the expandable member. In additional variations, theobturator can include one or more lumens for a guidewire or other suchdevice. In an additional variation, the expandable member 108 can belocated on a recess on the device 106 such that a diameter of theexpandable member in a reduced profile is no greater than a diameter ofthe catheter body of the device.

FIG. 7A illustrates a partial cross sectional view of the device 106with an obturator 110 extended therethrough when a flow of an infusionsubstance 3 is diverted into the expandable member 108. As illustrated,the device 106 can include one or more valves 114. The valves can be anystructure that permits flow of the infusion substance 3 into theexpandable member 108 and prevents the infusion substance from leavingthe expandable member until desired. In one example, the valve cancomprises a reed valve.

Once the expandable member 108 is sufficiently expanded, either byforming a seal against the walls of the vessel to stop arterial bloodflow, reaching a desired pressure, delivery of a volume of the infusionsubstance, etc. the flow resistance at the distal end 112 of the device106 can be reduced (e.g., by removing the dilator as shown in FIG. 7B)such that the flow of the infusion substance 3 extends through thedevice 106 and out of the distal end 112. In alternate variations, thedilator 110 can remain within the occlusion device 106 such that whenpressure in the expandable member 108 reaches a threshold value, flow ofthe infusion substance is automatically directed through the distal end112.

FIG. 8A illustrates a portion of the device 106 without the expandablemember. As shown, the valve 114 is in a closed position and allows flowof the infusion material from within the lumen of the device 106 intothe expandable member. The valve 114 remains closed in the absence ofpressure or flow from the device 106 lumen such that fluid within theexpandable member cannot exit through the valve.

FIG. 8B illustrates a variation of the device 106 using a valve releasemechanism 116 to open the valve and reduce the expandable member. Therelease mechanism can comprise any spring loaded structure that opensthe valve 116 (or a separate valve). In one variation, the releasemechanism 116 can be located on a portion of the dilator 110, such thata physician can position the release mechanism 116 adjacent to the valve114 when desired. Clearly, alternate variations of the device include aseparate release mechanism.

The device described above provides an improvement over conventionaldevices by maximizing the internal size of the infusion lumen whileminimizing the external size of the catheter by eliminating the need fora separate inflation lumen. In additional variations, the obturator ordevice used to expand the expandable member can be a color that isdifferent than a color of the device used to drain the expandablemember. For example, the filling obturator can be green while thedraining obturator can be red.

Any of the variations described above can include an indicator that theexpandable member is in the expanded state. Such an indicator couldprevent attempted removal of the device from the vessel when expanded.The indicator can be a radiopaque marking, or other conventional tag toprovide the status of the expandable member to the user.

Naturally, the system may include a variation of the aboveconfigurations. Variations of the device may include systems that havevarious decorations on the outer surface to make the system morechild-friendly and alleviate apprehension of getting an injection. Inthese devices and methods, the conditions may be those as describedabove, or other conditions as required by the specific treatment sought.

While embodiments and applications of this invention have been shown anddescribed, it would be apparent to those skilled in the art having thebenefit of this disclosure that many more modifications than mentionedabove are possible without departing from the inventive concepts herein.The invention, therefore, is not to be restricted except in the spiritof the appended claims.

What is claimed is:
 1. A method of resuscitating a patient consistingof: accessing an arterial vessel; positioning a catheter into thearterial vessel that supplies blood to a heart and a brain; providing aflow of infused blood through the catheter; increasing a resistance offluid flow at a distal end of the catheter such that the flow of infusedblood expands an expandable portion of the catheter to prevent arterialblood from flowing past the expanded portion in the arterial vessel; andreducing the resistance of fluid flow at the distal end of the cathetersuch that the infused blood exits the distal end of the catheter and thearterial vessel between the heart and the expandable portion of thecatheter.
 2. The method of claim 1 where accessing the arterial vesselinvolves identifying a location of the arterial vessel by a techniqueselected from the group consisting of: a) feeling for a pulse andinserting an access device at the pulse; b) using ultrasound; c) usingan electric field; d) using a magnetic field disturbance; and e) usingtissue density differences.
 3. The method of claim 1 where positioningthe catheter further comprises: placing a needle through a skin andoverlying tissue into the arterial vessel; placing a wire through theneedle; and placing the catheter over the needle or over the wire afterremoving the needle.
 4. The method of claim 1 further comprisingdetermining a position below the arterial vessel supplying blood to theheart and the brain by a technique selected from the group consistingof: a) determining a distance from an access site to a desired positionexternal to the patient and advancing the catheter to a predetermineddistance; b) using xray to place the catheter into appropriate positionand to verify that the catheter is in appropriate position; c) detectinga signal from the catheter using a modality selected from the groupconsisting of light, sound, ultrasonic, heat, cold, and electromagneticenergy to determine placement position.
 5. The method of claim 1 wherethe catheter comprises a device selected from the group consisting of a)a balloon catheter; b) a catheter with an umbrella structure; c) acatheter having a mechanically expanding spheroid.
 6. The method ofclaim 1 where providing the flow of infused blood through the cathetercomprises additionally infusing a substance selected from the groupcomprising an oxygen carrier selected from the group consisting of aperflourocarbon, a calcium substance, an EDTA, a saline fluid, a coolingfluid and a warming fluid.
 7. The method of claim 1 where the flow iscontinuous.
 8. The method of claim 1 where the flow is pulsatile.
 9. Themethod of claim 1 where the flow is at a rate and or pressure sufficientto close an aortic valve.